The Application Notebook
A novel method for the retention and quantification of polar neurotransmitters is presented. A reversed phase method using Scherzo SS-C18 column is compared to a HILIC method using a Polyhydroxyethyl column.
When analyzing highly polar compounds by reversed phase HPLC there exist several challenges, the most obvious of which is that polar compounds are difficult to retain using non-polar stationary phases like C18. A common solution is the use of aqueous normal phase or HILIC methods with stationary phases that can be wetted and that retain this aqueous layer on the surface of the particle. The difficulty in using HILIC methods is that the wetting process can often be quite lengthy, and maintaining a consistent aqueous surface is difficult.
In the example shown here we seek to provide an alternative to HILIC methods by using a novel multi-mode column called the Scherzo SS-C18. This stationary phase has both reversed-phase (C18) and polar components with the addition of a high density of strong anion and cation exchange ligands. This strategy for increasing polar retention is much more predictable run to run and does not require lengthy column pre-treatments.
MRM transitions and running conditions are within chromatograms.
Experimental data courtesy of Dr. D. Koop, Oregon Health and Sciences University, Portland, OR.
Chromatograms of the neurotransmitter acetylcholine using Scherzo SS-C18 and HILIC columns are shown in Figure 1 and Figure 2, respectively.
Both columns shown in Figure 1 and in Figure 2 retain the neurotransmitter acetylcholine well. Two instant observations are peak shape and detection limits. In particular, despite longer retention (~ 20% more), the peak shape on Scherzo SS-C18 is better as evident by peak width at half height which is about 50% of the HILIC column. This observation indicates overall significantly better performance of a Scherzo SS-C18 column and higher peak capacity that leads to better separations. This also contributes to a roughly 2.5X increase in sensitivity with the Scherzo SS-C18 column compared to the HILIC column (125 pg vs. 300 pg).
At approximately 3 min of retention, both methods can be justified for high throughout applications, however, considering the long and kinetically-slow conditioning on the HILIC column, we feel that Scherzo SS C-18 is a better choice. In contrast, the HILIC column, while it has comparable run times, requires over 2.5 h conditioning in this application, practically disqualifying this HILIC column for high throughput use.
The multi-mode Scherzo SS-C18 column shows great promise in successful retention of small, polar molecules (e.g., neurotransmitters). The column retains these types of analytes as well or better than a HILIC column, it has excellent sensitivity, eluents are MS-friendly, and, most importantly, it does not need lengthy conditioning. This feature alone significantly reduces overall separation times and operation costs, which potentially makes this column an attractive alternative for separation of polar analytes.
Imtakt USA
1104 NW Overton St., Portland, OR 97209
tel. (888) 456-HPLC, (215) 665-8902, fax (501) 646-3497
Website: www.imtaktusa.com
Mitigating High Sample Volume Consumption in AAV Aggregate Analysis Using a Biozen™ dSEC-7 by SEC-FL
April 15th 2024This application note showcases a Biozen dSEC-7 SEC chemistry/fluorescence detector solution, offering reliable AAV aggregate analysis in under 10 minutes with as little as 0.5 µL of sample. Across four AAV serotypes, resolution between monomer and aggregates remains consistently high, emphasizing Biozen dSEC-7's efficiency and ability to maintain accurate detection at minimal injection volumes. Ideal for routine testing, this solution ensures precise measurement of a CQA with streamlined sample consumption.
Adeno-Associated Virus (AAV) Serotype Screen Using a Biozen™ dSEC-7 Size Exclusion Column
April 15th 2024With its 700 Å large pore silica particle and hydrophilic diol-type surface chemistry, Biozen dSEC-7 provides excellent resolution of monomer from dimer peaks in under 8 minutes across four different AAV serotypes. This capability is crucial for optimizing gene therapy biopharmaceuticals, ensuring thorough analytical scrutiny to select the most appropriate serotype(s) for enhanced therapeutic outcomes and immunogenic profiles.